Physician profile
Devang S Parikh
NPI 1609131762
$17,209.34
in general payments reported to CMS, 2019-2025
41 companies · $927 in 2025
The $927 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,063 · 2020: $202 · 2021: $1,722 · 2022: $5,161 · 2023: $1,168 · 2024: $966 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,060.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $6,706.72 | 2019-2020 | |
| Edwards Lifesciences Corporation | $2,764.66 | 2020-2024 | Mitris Resilia Mitral Valve |
| Abbott Laboratories | $2,706.26 | 2019-2025 | Cardiomems, Mitraclip, Confirm Rx |
| Novartis Pharmaceuticals Corporation | $811.77 | 2021-2025 | |
| Boston Scientific Corporation | $734.36 | 2021-2025 | Watchman Flx, Watchman Access System, Wolverine Coronary Cutting Balloon |
| Impulse Dynamics (USA) INC. | $539.68 | 2021-2025 | Optimizer, Optimizer |
| Abiomed | $254.66 | 2023-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $254.44 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $239.29 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $235.98 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $184.89 | 2021-2025 | Verquvo |
| Medtronic, INC. | $162.60 | 2022-2025 | Corevalve Evolut R, Avalus |
| Esperion Therapeutics, INC. | $145.91 | 2022 | |
| Astellas Pharma US INC | $144.09 | 2025 | Izervay |
| Kestra Medical Technology Services, INC. | $135.80 | 2024-2025 | Assure Wcd |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devang Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.